113 related articles for article (PubMed ID: 23524101)
1. Different effect of sodium butyrate on cancer and normal prostate cells.
Paskova L; Smesny Trtkova K; Fialova B; Benedikova A; Langova K; Kolar Z
Toxicol In Vitro; 2013 Aug; 27(5):1489-95. PubMed ID: 23524101
[TBL] [Abstract][Full Text] [Related]
2. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
3. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
[TBL] [Abstract][Full Text] [Related]
4. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells.
Kim J; Park H; Im JY; Choi WS; Kim HS
Anticancer Res; 2007; 27(5A):3285-92. PubMed ID: 17970072
[TBL] [Abstract][Full Text] [Related]
5. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
7. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
8. Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB.
Trtkova K; Paskova L; Matijescukova N; Strnad M; Kolar Z
Neoplasma; 2010; 57(5):406-14. PubMed ID: 20568894
[TBL] [Abstract][Full Text] [Related]
9. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.
Kinoshita M; Nakagawa T; Shimizu A; Katsuoka Y
Int J Urol; 2005 Apr; 12(4):390-7. PubMed ID: 15948728
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modulation of AR gene expression in prostate cancer DU145 cells with the combination of sodium butyrate and 5'-Aza-2'-deoxycytidine.
Fialova B; Luzna P; Gursky J; Langova K; Kolar Z; Trtkova KS
Oncol Rep; 2016 Oct; 36(4):2365-74. PubMed ID: 27499010
[TBL] [Abstract][Full Text] [Related]
11. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers.
Ren G; Zhang G; Dong Z; Liu Z; Li L; Feng Y; Su D; Zhang Y; Huang B; Lu J
Int J Biochem Cell Biol; 2009 May; 41(5):1094-101. PubMed ID: 19013255
[TBL] [Abstract][Full Text] [Related]
12. Regulation of T-type calcium channel expression by sodium butyrate in prostate cancer cells.
Weaver EM; Zamora FJ; Puplampu-Dove YA; Kiessu E; Hearne JL; Martin-Caraballo M
Eur J Pharmacol; 2015 Feb; 749():20-31. PubMed ID: 25557765
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants.
Korkmaz CG; Frønsdal K; Zhang Y; Lorenzo PI; Saatcioglu F
J Endocrinol; 2004 Sep; 182(3):377-89. PubMed ID: 15350180
[TBL] [Abstract][Full Text] [Related]
14. Hypoacetylation, hypomethylation, and dephosphorylation of H2B histones and excessive histone deacetylase activity in DU-145 prostate cancer cells.
Cang S; Xu X; Ma Y; Liu D; Chiao JW
J Hematol Oncol; 2016 Jan; 9():3. PubMed ID: 26759222
[TBL] [Abstract][Full Text] [Related]
15. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S
Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA
Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
19. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
[TBL] [Abstract][Full Text] [Related]
20. Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor.
Choi KC; Park S; Lim BJ; Seong AR; Lee YH; Shiota M; Yokomizo A; Naito S; Na Y; Yoon HG
Biochem J; 2011 Jan; 433(1):235-44. PubMed ID: 20955177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]